142 results
8-K
EX-99.2
ATOS
Atossa Therapeutics Inc
25 Oct 17
Atossa Genetics Announces Preliminary Results from
12:00am
Atossa Genetics Overview Endoxifen Phase 1 Study Summaries – Safety – Tolerability – Pharmacokinetics Upcoming Milestones 3
Atossa Genetics Overview 4 … Demonstrated: - Safety - Tolerability - Verification of therapeutic blood levels Supports continued development Preliminary Phase 1 Oral Results 24
Q2 2016
8-K
EX-99.2
ATOS
Atossa Therapeutics Inc
13 Sep 18
Atossa Genetics Announces Preliminary Results from
12:00am
98104 2
DISCUSSION TOPICS Atossa Genetics Overview Endoxifen Phase 1 Study Preliminary Safety Summary Preliminary Tolerability Summary Preliminary … Topical Results Study objectives achieved Demonstrated: - No Safety Issues - No Tolerability Issues - Topical Endoxifen not detected in the blood stream
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
25 Oct 17
Atossa Genetics Announces Preliminary Results from
12:00am
of its proprietary oral Endoxifen. All objectives were successfully met:
Safety: There were no clinically significant safety signals and no clinically … .
The Phase 1 Study
The Phase 1 study was a double-blind, placebo-controlled, repeat dose study of 48 healthy female subjects. Atossa assessed safety
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
13 Sep 18
Atossa Genetics Announces Preliminary Results from
12:00am
results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects. All objectives were successfully met:
Safety … : There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen
FWP
ATOS
Atossa Therapeutics Inc
16 May 18
Free writing prospectus
2:39pm
; safety and tolerability Placebo controlled, double - blinded 49 female volunteers Oral (single and repeat dose) and topical (28 - day repeat dose … ) arms at varying dose levels Endoxifen – Phase 1 Clinical Trial 15
Safety : no clinically significant safety signals and no clinically significant
8-K
EX-99.1
va2jw2
28 Mar 19
Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
4:32pm
8-K
EX-99.1
gw8hk5yh
13 May 19
Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update
4:30pm
8-K
n8o65kqba05xbn sz9
15 Oct 19
Other Events
12:08pm
8-K
EX-99
6thjuv7853p fgz
17 May 18
Atossa Genetics Announces First Quarter 2018 Financial Results
12:16pm
8-K
EX-99.1
snsmaa
13 Nov 20
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
9:30am
8-K
EX-99.1
g0jrd
31 Mar 21
Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update
9:01am
8-K
EX-99.1
knffx7v3z0gsl87
13 Aug 18
Atossa Genetics Announces Second Quarter 2018 Financial Results
4:18pm